Skip to Content
PharmaceuticsPharmaceutics
  • Correction
  • Open Access

9 July 2025

Correction: Balas et al. Photodynamic Activity of TMPyP4/TiO2 Complex under Blue Light in Human Melanoma Cells: Potential for Cancer-Selective Therapy. Pharmaceutics 2023, 15, 1194

,
,
,
,
,
,
,
,
and
1
Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, 91-95 Splaiul Independentei, 050095 Bucharest, Romania
2
Laser Department, National Institute of Laser, Plasma, and Radiation Physics, 409 Atomistilor Str., 077125 Magurele, Romania
3
Research Institute of the University of Bucharest (ICUB), University of Bucharest, 90-92 Sos. Panduri, 050663 Bucharest, Romania
*
Authors to whom correspondence should be addressed.

Error in Figure

In the original publication [1], there was a mistake in Figure 8, as published. The image “g” from Figure 8A, representing Mel-Juso cells treated with the TMPyP4/TiO2 complex, was incorrectly placed in the original publication. The corrected Figure 8 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Figure 8. LIVE/DEAD staining on treated Mel-Juso (A) and CCD-1070Sk cells (B) after light irradiation for 7.5 min. Cells were treated with different concentrations of TMPyP4: 0.5 μg/mL (a), 0.75 μg/mL (b), and 1 μg/mL (c); TiO2 NPs: 20 μg/mL (d), 30.7 μg/mL (e) and 40 μg/mL (f) and TMPyP4/TiO2 complex: 0.5/20 μg/mL (g), 0.75/30.7 μg/mL (h), 1/40 μg/mL (i). Control cells (Ctrl) are non-treated, and light irradiated. Live cells are stained with calcein AM (green fluorescence), and dead cells with ethidium homodimer (red fluorescence). The scale bar is the same for all images and is 100 µm.

Reference

  1. Balas, M.; Nistorescu, S.; Badea, M.A.; Dinischiotu, A.; Boni, M.; Dinache, A.; Smarandache, A.; Udrea, A.-M.; Prepelita, P.; Staicu, A. Photodynamic Activity of TMPyP4/TiO2 Complex under Blue Light in Human Melanoma Cells: Potential for Cancer-Selective Therapy. Pharmaceutics 2023, 15, 1194. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.